In the BioHarmony Drug Report Database
Humulin N, Actrapid (insulin) is a protein pharmaceutical. Insulin was first approved as Humulin N on 2002-10-07. It has been approved in Europe to treat diabetes mellitus. The pharmaceutical is active against insulin receptor, insulin-like growth factor II, and insulin-like growth factor I. In addition, it is known to target relaxin-3 receptor 1, relaxin receptor 2, transient receptor potential cation channel subfamily V member 2, relaxin receptor 1, relaxin-3 receptor 2, and insulin-like growth factor 1 receptor.
Image (chem structure or protein)